222 related articles for article (PubMed ID: 31079574)
1. Predictive Value of 99MTC-hynic-toc Scintigraphy in Lung Neuroendocrine Tumor Diagnosis.
Boutsikou E; Porpodis K; Chatzipavlidou V; Hardavella G; Gerasimou G; Domvri K; Papadopoulos N; Avramidou V; Spyratos D; Kontakiotis T; Zarogoulidis K
Technol Cancer Res Treat; 2019 Jan; 18():1533033819842586. PubMed ID: 31079574
[TBL] [Abstract][Full Text] [Related]
2. Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs).
Sergieva S; Robev B; Dimcheva M; Fakirova A; Hristoskova R
Nucl Med Rev Cent East Eur; 2016; 19(2):81-7. PubMed ID: 27479885
[TBL] [Abstract][Full Text] [Related]
3. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
Trogrlic M; Tezak S
Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884
[TBL] [Abstract][Full Text] [Related]
4. 99mTc-EDDA/HYNIC-TOC somatostatin receptor scintigraphy in daily clinical practice.
Chrapko BE; Nocuń A; Gołebiewska R; Stefaniak B; Korobowicz E; Czekajska-Chehab E; Sawicki M; Polkowski WP
Med Sci Monit; 2010 Apr; 16(4):MT35-44. PubMed ID: 20357727
[TBL] [Abstract][Full Text] [Related]
5. Limitations and pitfalls of 99mTc-EDDA/HYNIC-TOC (Tektrotyd) scintigraphy.
Garai I; Barna S; Nagy G; Forgacs A
Nucl Med Rev Cent East Eur; 2016; 19(2):93-8. PubMed ID: 27479887
[TBL] [Abstract][Full Text] [Related]
6. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
[TBL] [Abstract][Full Text] [Related]
7. [99mTc-OCTREOTIDE in patients with neuroendocrine tumors from the GI tract].
Gómez M; Ferrando R; Vilar J; Hitateguy R; López B; Moreira E; Kapitán M; De Lima F; Agüero B; Gabriela Villegas M; Urdaneta N; Gutiérrez E; Battegazzore A; Bayardo K; Silveira A; Lago G; Páez A
Acta Gastroenterol Latinoam; 2010 Dec; 40(4):332-8. PubMed ID: 21381408
[TBL] [Abstract][Full Text] [Related]
8. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
9. Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy.
de la Cueva L; Lloro P; Sangrós MJ; López Vélez L; Navarro P; Sarria L; Álvarez S; Abós D
Clin Transl Oncol; 2017 Jul; 19(7):915-920. PubMed ID: 28144828
[TBL] [Abstract][Full Text] [Related]
10.
Briganti V; Cuccurullo V; Berti V; Di Stasio GD; Linguanti F; Mungai F; Mansi L
Curr Radiopharm; 2020; 13(3):166-176. PubMed ID: 31886756
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of scintigraphy of neuroendocrine tumors using (99m)Tc-HYNIC-TOC.
Artiko V; Sobic-Saranovic D; Pavlovic S; Petrovic M; Zuvela M; Antic A; Matic S; Odalovic S; Petrovic N; Milovanovic A; Obradovic V
J BUON; 2012; 17(3):537-42. PubMed ID: 23033296
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of 99mTc-depreotide and 99mTc-EDDA/HYNIC-TOC thorax scintigrams acquired for the purpose of differential diagnosis of solitary pulmonary nodules.
Płachcińska A; Mikołajczak R; Kozak J; Rzeszutek K; Kuśmierek J
Nucl Med Rev Cent East Eur; 2006; 9(1):24-9. PubMed ID: 16791800
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC.
Artiko V; Afgan A; Petrović J; Radović B; Petrović N; Vlajković M; Šobić-Šaranović D; Obradović V
Nucl Med Rev Cent East Eur; 2016; 19(2):99-103. PubMed ID: 27479786
[TBL] [Abstract][Full Text] [Related]
14. Incremental value of
Trogrlic M; Težak S
Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of somatostatin receptors in large cell pulmonary neuroendocrine carcinoma with 99mTc-EDDA/HYNIC-TOC scintigraphy.
Nocuń A; Chrapko B; Gołębiewska R; Stefaniak B; Czekajska-Chehab E
Nucl Med Commun; 2011 Jun; 32(6):522-9. PubMed ID: 21383640
[TBL] [Abstract][Full Text] [Related]
16. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
Cwikla JB; Mikolajczak R; Pawlak D; Buscombe JR; Nasierowska-Guttmejer A; Bator A; Maecke HR; Walecki J
J Nucl Med; 2008 Jul; 49(7):1060-5. PubMed ID: 18552141
[TBL] [Abstract][Full Text] [Related]
17. 99mTc-HYNIC-TOC imaging in the evaluation of pancreatic masses which are potential neuroendocrine tumors.
Qiao Z; Zhang J; Jin X; Huo L; Zhu Z; Xing H; Li F
Clin Nucl Med; 2015 May; 40(5):397-400. PubMed ID: 25706799
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of 99mTc EDDA/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumour uptake using SPECT/CT standardised uptake values: initial experience.
Reilly C; Gemmell AJ; McLaughlin IM; Fleming R; Reed N; McIntosh D; Nicol A
Nucl Med Commun; 2021 Aug; 42(8):935-939. PubMed ID: 33741866
[TBL] [Abstract][Full Text] [Related]
19. Role of 99mTc-HYNIC-Tyr3-octreotide scintigraphy in neuroendocrine tumors based on localization of the primary tumor.
Jimenez Londoño GA; García Vicente AM; Soriano Castrejon AM; Gómez López OV; Palomar Muñoz A; Vega Caicedo CH; Cordero García JM
Minerva Endocrinol; 2016 Mar; 41(1):10-8. PubMed ID: 25582872
[TBL] [Abstract][Full Text] [Related]
20. Clinical application of
Xu J; Li Y; Xu X; Zhang J; Zhang Y; Yu X; Huang D
Ann Nucl Med; 2018 Aug; 32(7):446-452. PubMed ID: 29926342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]